Estrogen-Free Oral Hormonal Contraception: Benefits of the Progestin-Only Pill

Women's Health

Volumn 6, Issue 5, 2010, Pages 721-735

  de Melo, Nilson Roberto ^a  

^a Federaçao Brasileira das Sociedades de Ginecologia e Obstetricia ^*  (Brazil)

Author keywords

combined oral contraceptive; counseling; cycle control; dysmenorrhea; estrogen; hormonal contraceptive; progestin only pill

Indexed keywords

GESTAGEN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DYSMENORRHEA; FEMALE; HUMAN; MENSTRUATION; PATIENT COMPLIANCE; REVIEW; STANDARD;

CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DYSMENORRHEA; FEMALE; HUMANS; MEDICATION ADHERENCE; MENSTRUATION; NORETHINDRONE; PROGESTINS;

EID: 79952277785     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/WHE.10.36     Document Type: Review

References (124)

1. Papers of special note have been highlighted as:.
2. of interest
3. Speroff L: A Clinical Guide for Contraception (2nd Ed). Williams and Wilkins, Baltimore, MD, USA (1996).
4. Milsom I Korver T: Ovulation incidence with oral contraceptives: a literature review. J. Fam. Plann. Reprod. Health Care 34(4), 237–246 (2008).
5. Trussell J: Contraceptive efficacy. In: Contraceptive Technology. Hatcher RA Trussell J Nelson AL Cates W Jr Stewart FH Kowal D (Eds), Ardent Media Inc., NY, USA, 747–826 (2007).
6. Kaunitz AM: Oral contraceptive health benefits: perception versus reality. Contraception 59(1 Suppl.), 29S–33S (1999).
7. Hannaford PC Iversen L Macfarlane TV Elliott AM Angus V Lee AJ: Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 340, c927 (2010).
8. Chandra A Martinez MG Mosher WD Abma JC Jones J: Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat. 23(25), 1–160 (2005).
9. Wallach M Grimes DA Chaney EJ et al.: Modern oral contraception: Updates from the Contraception Report. Emron Inc., NJ, USA (2000).
10. Raymond EG: Progestin-only pills. In: Contraceptive Technology. Hatcher RA Trussell J Nelson AL et al. (Eds), Ardent Media Inc., NY, USA, 181–191 (2007).
11. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill: A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur. J. Contracept. Reprod. Health Care 3(4), 169–178 (1998).
12. In this double-blind, randomized comparative trial, 989 subjects were randomized to desogestrel 75 μg/day and 331 subjects to levonorgestrel 30 μg/day, and observed during 13 consecutive 28-day treatment periods. Desogestrel demonstrated superior contraceptive efficacy and similar overall acceptability compared with levonorgestrel.
13. Hammond GL Rabe T Wagner JD: Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am. J. Obstet. Gynecol. 185(2 Suppl.), S24–S31 (2001).
14. Vandenbroucke JP Koster T Briet E Reitsma PH Bertina RM Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344(8935), 1453–1457 (1994).
15. Godsland IF Winkler U Lidegaard O Crook D: Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 60(4), 721–869 (2000).
16. Dinger JC Heinemann LA Kuhl-Habich D: The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5), 344–354 (2007).
17. A total of 58,674 women were followed for 142,475 women-years. Combined oral contraceptive (COC) use was associated with a risk of venous thromboembolism that ranged from approximately 8–10 per 10,000 woman-years; this level of risk was higher than that associated with non-COC use, but lower than that associated with pregnancy. Cardiovascular risk appeared to be similar among women using COCs containing drospirenone and those using other COCs.
18. Jick H Jick SS Gurewich V Myers MW Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346(8990), 1589–1593 (1995).
19. Bloemenkamp KW Rosendaal FR Helmerhorst FM Buller HR Vandenbroucke JP: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346(8990), 1593–1596 (1995).
20. WHO: Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346(8990), 1582–1588 (1995).
21. Spitzer WO Lewis MA Heinemann LA Thorogood M MacRae KD: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case–control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312(7023), 83–88 (1996).
22. Heinemann LA: The changing scene – an unnecessary pill crisis. Hum. Reprod. Update 5(6), 746–755 (1999).
23. Kemmeren JM Algra A Grobbee DE: Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323(7305), 131–134 (2001).
24. Heinemann LA Lewis MA Assmann A Thiel C: Case–control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 65(3), 207–214 (2002).
25. Farmer RD Lawrenson RA Todd JC et al.: A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br. J. Clin. Pharmacol. 49(6), 580–590 (2000).
26. Suissa S Blais L Spitzer WO Cusson J Lewis M Heinemann L: First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56(3), 141–146 (1997).
27. Lewis MA MacRae KD Kuhl-Habichl D Bruppacher R Heinemann LA Spitzer WO: The differential risk of oral contraceptives: the impact of full exposure history. Hum. Reprod. 14(6), 1493–1499 (1999).
28. Lewis MA: The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect. Hum. Reprod. Update 5(6), 707–720 (1999).
29. Heinemann LA Garbe E Farmer R Lewis MA: Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur. J. Contracept. Reprod. Health Care 5(3), 183–191 (2000).
30. Suissa S Spitzer WO Rainville B Cusson J Lewis M Heinemann L: Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum. Reprod. 15(4), 817–821 (2000).
31. Todd J Lawrenson R Farmer RD Williams TJ Leydon GM: Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum. Reprod. 14(6), 1500–1505 (1999).
32. Farmer RD Lawrenson RA Thompson CR Kennedy JG Hambleton IR: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349(9045), 83–88 (1997).
33. Farmer RD Todd JC Lewis MA MacRae KD Williams TJ: The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 57(2), 67–70 (1998).
34. Spannagl M Heinemann LA Schramm W: Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur. J. Contracept. Reprod. Health Care 5(2), 105–112 (2000).
35. Wu O Robertson L Langhorne P et al.: Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb. Haemost. 94(1), 17–25 (2005).
36. Baillargeon JP McClish DK Essah PA Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab. 90(7), 3863–3870 (2005).
37. Ageno W Becattini C Brighton T Selby R Kamphuisen PW: Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117(1), 93–102 (2008).
38. Shufelt CL Merz Bairey CN: Contraceptive hormone use and cardiovascular disease. J. Am. Coll. Cardiol. 53(3), 221–231 (2009).
39. Sidney S Siscovick DS Petitti DB et al.: Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 98(11), 1058–1063 (1998).
40. Khader YS Rice J John L Abueita O: Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 68(1), 11–17 (2003).
41. Jick H Jick S Myers MW Vasilakis C: Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 347(9001), 627–628 (1996).
42. Lewis MA Spitzer WO Heinemann LA MacRae KD Bruppacher R Thorogood M: Third generation oral contraceptives and risk of myocardial infarction: an international case–control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312(7023), 88–90 (1996).
43. Lewis MA Heinemann LA Spitzer WO MacRae KD Bruppacher R: The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56(3), 129–140 (1997).
44. WHO: Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case–control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 349(9060), 1202–1209 (1997).
45. Dunn N Thorogood M Faragher B et al.: Oral contraceptives and myocardial infarction: results of the MICA case–control study. BMJ 318(7198), 1579–1583 (1999).
46. Tanis BC van den Bosch MA Kemmeren JM et al.: Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med. 345(25), 1787–1793 (2001).
47. Spitzer WO Faith JM MacRae KD: Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum. Reprod. 17(9), 2307–2314 (2002).
48. Gillum LA Mamidipudi SK Johnston SC: Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 284(1), 72–78 (2000).
49. Chan WS Ray J Wai EK et al.: Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch. Intern. Med. 164(7), 741–747 (2004).
50. Buring JE Hebert P Romero J et al.: Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch. Neurol. 52(2), 129–134 (1995).
51. Chang CL Donaghy M Poulter N: Migraine and stroke in young women: case–control study. The WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 318(7175), 13–18 (1999).
52. Vargas BB Dodick DW Wingerchuk DM Demaerschalk BM: Migraine with and without aura and risk for cardiovascular disease. Curr. Atheroscler. Rep. 10(5), 427–433 (2008).
53. Etminan M Takkouche B Isorna FC Samii A: Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330(7482), 63 (2005).
54. Curtis KM Mohllajee AP Martins SL Peterson HB: Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 73(2), 179–188 (2006).
55. Goldstein LB Adams R Alberts MJ et al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113(24), e873–e923 (2006).
56. Farley TM Meirik O Chang CL Poulter NR: Combined oral contraceptives, smoking, and cardiovascular risk. J. Epidemiol. Community Health 52(12), 775–785 (1998).
57. Farley TM Collins J Schlesselman JJ: Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 57(3), 211–230 (1998).
58. Godsland IF Crook D Simpson R et al.: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med. 323(20), 1375–1381 (1990).
59. Wynn V Adams PW Godsland I et al.: Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1(8125), 1045–1049 (1979).
60. Simon D Senan C Garnier P et al.: Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. Am. J. Obstet. Gynecol. 163(1 Pt 2), 382–387 (1990).
61. Wynn V Godsland I: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Med. 31(9 Suppl.), 892–897 (1986).
62. Lopez LM Grimes DA Schulz KF: Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst. Rev. 2, CD006133 (2007).
63. Skouby SO Endrikat J Dusterberg B et al.: A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception 71(2), 111–117 (2005).
64. Winkler UH Sudik R: The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception 79(1), 15–23 (2009).
65. Klipping C Marr J: Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71(6), 409–416 (2005).
66. Grigoryan OR Grodnitskaya EE Andreeva EN Shestakova MV Melnichenko GA Dedov II: Contraception in perimenopausal women with diabetes mellitus. Gynecol. Endocrinol. 22(4), 198–206 (2006).
67. Skouby SO Molsted-Pedersen L Kuhl C Bennet P: Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertil. Steril. 46(5), 858–864 (1986).
68. Radberg T Gustafson A Skryten A Karlsson K: Oral contraception in diabetic women. A cross-over study on serum and high density lipoprotein (HDL) lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Horm. Metab. Res. 14(2), 61–65 (1982).
69. Visser J Snel M van Vliet HA: Hormonal versus non-hormonal contraceptives in women with diabetes mellitus Type 1 and 2. Cochrane Database Syst. Rev. (4), CD003990 (2006).
70. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N. Engl. J. Med. 316(11), 650–655 (1987).
71. Henderson BE Casagrande JT Pike MC Mack T Rosario I Duke A: The epidemiology of endometrial cancer in young women. Br. J. Cancer 47(6), 749–756 (1983).
72. Hulka BS Chambless LE Kaufman DG Fowler WC Jr Greenberg BG: Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247(4), 475–477 (1982).
73. Kaufman DW Shapiro S Slone D et al.: Decreased risk of endometrial cancer among oral-contraceptive users. N. Engl. J. Med. 303(18), 1045–1047 (1980).
74. Kelsey JL LiVolsi VA Holford TR et al.: A case–control study of cancer of the endometrium. Am. J. Epidemiol. 116(2), 333–342 (1982).
75. Weiss NS Sayvetz TA: Incidence of endometrial cancer in relation to the use of oral contraceptives. N. Engl. J. Med. 302(10), 551–554 (1980).
76. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017), 1713–1727 (1996).
77. The Collaborative Group on Hormonal Factors in Breast Cancer analyzed data from 53,297 women with breast cancer and 100,239 women without breast cancer from 54 studies. Findings showed a small increase in relative risk of breast cancer among women currently using COCs and those who had used COCs in the previous 1–9 years; and, no significant excess risk of breast cancer at least 10 years after women discontinued COC use.
78. Grabrick DM Hartmann LC Cerhan JR et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284(14), 1791–1798 (2000).
79. Kahlenborn C Modugno F Potter DM Severs WB: Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin. Proc. 81(10), 1290–1302 (2006).
80. Marchbanks PA McDonald JA Wilson HG et al.: Oral contraceptives and the risk of breast cancer. N. Engl. J. Med. 346(26), 2025–2032 (2002).
81. WHO: Medical Eligibility Criteria for Contraceptive Use (3rd Edition). Reproductive Health and Research, WHO, Geneva, Switzerland (2004).
82. International Planned Parenthood Federation International Medical Advisory Panel: IMAP statement on hormonal methods of contraception. IPPF Med. Bull. 36(5), 1–8 (2002).
83. Truitt ST Fraser AB Grimes DA Gallo MF Schulz KF: Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst. Rev. 2, CD003988 (2003).
84. Gallo MF Nanda K Grimes DA Lopez LM Schulz KF: 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst. Rev. 4, CD003989 (2008).
85. Loder EW Buse DC Golub JR: Headache as a side effect of combination estrogen–progestin oral contraceptives: a systematic review. Am. J. Obstet. Gynecol. 193(3 Pt 1), 636–649 (2005).
86. Silberstein SD: Hormone-related headache. Med. Clin. North Am. 85(4), 1017–1035 (2001).
87. Sulak PJ Scow RD Preece C Riggs MW Kuehl TJ: Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95(2), 261–266 (2000).
88. Allais G Bussone G Airola G et al.: Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol. Sci. 29(Suppl. 1), S186–S190 (2008).
89. Hatcher RA Guillebaud J: The pill: combined oral contraceptives. In: Contraceptive Technology. Hatcher RA Trussel J Stewart F (Eds), Ardent Media Inc., NY, USA, 405–466 (1998).
90. Westhoff CL Heartwell S Edwards S et al.: Oral contraceptive discontinuation: do side effects matter? Am. J. Obstet. Gynecol. 196(4), 412 e411–e416; discussion 412 e416–e417 (2007).
91. Approximately 60% of 1716 COC women discontinued COC use by 6 months. Premature COC discontinuation was more likely in women with complaints, particularly headaches or moodiness.
92. Dawood MY: Primary dysmenorrhea: advances in pathogenesis and management. Obstet. Gynecol. 108(2), 428–441 (2006).
93. Bieglmayer C Hofer G Kainz C Reinthaller A Kopp B Janisch H: Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol. Endocrinol. 9(4), 307–312 (1995).
94. Proctor ML Roberts H Farquhar CM: Combined oral contraceptive pill (COP) as treatment for primary dysmenorrhoea. Cochrane Database Syst. Rev. 4, CD002120 (2001).
95. Rosenwaks Z Seegar-Jones G: Menstrual pain: its origin and pathogenesis. J. Reprod. Med. 25(4 Suppl.), 207–212 (1980).
96. Hendrix SL Alexander NJ: Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 66(6), 393–399 (2002).
97. Edelman AB Gallo MF Jensen JT Nichols MD Schulz KF Grimes DA: Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst. Rev. 3, CD004695 (2005).
98. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit: desogestrel-only pill (Cerazette). J. Fam. Plann. Reprod. Health Care 29(3), 162–164 (2003).
99. Korver T Klipping C Heger-Mahn D Duijkers I van Osta G Dieben T: Maintenance of ovulation inhibition with the 75 μg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 71(1), 8–13 (2005).
100. McCann MF Potter LS: Progestin-only oral contraception: a comprehensive review. Contraception 50(6 Suppl. 1), S1–S195 (1994).
101. Kloosterboer HJ Vonk-Noordegraaf CA Turpijn EW: Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 38(3), 325–332 (1988).
102. Rice CF Killick SR Dieben T Bennink Coelingh H: A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum. Reprod. 14(4), 982–985 (1999).
103. Randomized, double-blind, comparative study conducted over 12 months in 71 women using progestin-only pills (POPs) containing desogestrel 75 μg or levonorgestrel 30 μg. Desogestrel POP showed significant ovulation inhibition compared with levonorgestrel POP.
104. Blumenthal PD Edelman A: Hormonal contraception. Obstet. Gynecol. 112(3), 670–684 (2008).
105. International Collaborative Post-marketing Surveillance of Norplant: Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health. Contraception 63(4), 187–209 (2001).
106. WHO: Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 57(5), 315–324 (1998).
107. First study to examine the risks of cardiovascular disease associated with POP use: found little or no increased risk of venous thromboembolism, myocardial infarction or strokes in women using this method of contraception.
108. Shoupe D: Effects of desogestrel on carbohydrate metabolism. Am. J. Obstet. Gynecol. 168(3 Pt 2), 1041–1047 (1993).
109. McCann MF Moggia AV Higgins JE Potts M Becker C: The effects of a progestin-only oral contraceptive (levonorgestrel 0.03 mg) on breast-feeding. Contraception 40(6), 635–648 (1989).
110. Ahrendt HJ Karckt U Pichl T Mueller T Ernst U: The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur. J. Contracept. Reprod. Health Care 12(4), 354–361 (2007).
111. Two prospective studies conducted in Germany in 403 women with estrogen-related symptoms during prior COC use and 406 women with dysmenorrhea who took the desogestrel 75 μg POP. Resolution or improvement of estrogen-related symptoms in over 70% of women; and, resolution or considerable improvement in dysmenorrhea in 93% of women. Approximately 7–8% of women receiving POP in both studies reported adverse events, primarily bleeding abnormalities.
112. Paulsen ML Varaday A Brown BW Kalman SM: A andomized contraceptive trial comparing a daily progestogen with a combined oral contraceptive steroid. Contraception 9(5), 497–506 (1974).
113. Grimes DA Lopez LM O'Brien PA Raymond EG: Progestin-only pills for contraception. Cochrane Database Syst. Rev. 1, CD007541 (2010).
114. Porter C Rees MC: Bleeding problems and progestogen-only contraception. J. Fam. Plann. Reprod. Health Care 28(4), 178–181 (2002).
115. Sheth A Jain U Sharma S et al.: A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. Contraception 25(3), 243–252 (1982).
116. Davie JE Walling MR Mansour DJ Bromham D Kishen M Fowler P: Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin. Ther. 18(1), 150–159 (1996).
117. de Cetina Canto TE Canto P Luna Ordonez M: Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63(3), 143–146 (2001).
118. Hubacher D Goco N Gonzalez B Taylor D: Factors affecting continuation rates of DMPA. Contraception 60(6), 345–351 (1999).
119. Backman T Huhtala S Luoto R Tuominen J Rauramo I Koskenvuo M: Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet. Gynecol. 99(4), 608–613 (2002).
120. Based on a survey of 23,885 women in Finland who used a progestin-releasing intrauterine system, women's satisfaction with this contraceptive method was associated with the amount of information received. Women who received information about potential symptoms were more satisfied than less informed women.
121. United Nations Department of Economic and Social Affairs Population Division: World Contraception Use 2007 (2008) www.un.org/esa/population/publications/contraceptive2007/contraceptive2007.htm (Accessed April 2010).
122. Duramed Pharmaceuticals Inc: LoSeasonique™ tablets (levonorgestrel and ethinyl estradiol): physician labeling (2008) www.loseasonique.com/docs/prescribing-information.pdf (Accessed April 2010).
123. WHO: Providing an appropriate contraceptive method choice: what health workers need to know (1993) http://whqlibdoc.who.int/hq/1993/WHO_mch_fpp_93.3.pdf (Accessed April 2010).
124. Royal College of Obstetricians and Gynaecologists: UK Selected Practice Recommendations for Contraceptive Use (2002) www.ffprhc.org.uk/admin/uploads/SelectedPracticeRecommendations2002.pdf (Accessed April 2010).